S1 Table. Time to treatment discontinuation sensitivity analysis

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  | **The Netherlands** |  | **Belgium** |
|  |  |  | Paliperidone palmitate | Risperidone microspheres | Haloperidol decanoate | Olanzapine pamoate |  | Paliperidone palmitate | Risperidone microspheres | Haloperidol decanoate | Olanzapine pamoate |
| **Second period** | **Oct12-Sep13** |  | **Sep12-Sep13** |
|  |  | N | 524 | 411 | 373 | 92 |  | 813 | 568 | 401 | 136 |
|  | Percentage of patients remaining on treatment |  |  |  |  |  |
|  |  | *After one injection* | 91% | 92% | 86% | 86% |  | 81% | 75% | 68% | 90% |
|  |  | *After 6 months* | 65% | 48% | 52% | 51% |  | 46% | 35% | 25% | 37% |
|  |  | *After 12 months* | 43% | 30% | 33% | 39% |  | 34% | 25% | 16% | 24% |
|  | Percentage of patients remaining on treatment - Lower-bound |  |  |  |  |  |
|  |  | *After one injection* | 79% | 81% | 81% | 71% |  | 63% | 56% | 59% | 71% |
|  |  | *After 6 months* | 33% | 12% | 38% | 7% |  | 13% | 4% | 9% | 7% |
|  |  | *After 12 months* | 12% | 2% | 16% | 3% |  | 3% | 1% | 4% | 2% |
|  | Percentage of patients remaining on treatment - Upper-bound |  |  |  |  |  |
|  |  | *After one injection* | 93% | 94% | 87% | 88% |  | 89% | 83% | 75% | 92% |
|  |  | *After 6 months* | 73% | 58% | 59% | 60% |  | 65% | 53% | 42% | 51% |
|  |  | *After 12 months* | 51% | 39% | 40% | 47% |  | 47% | 35% | 27% | 35% |